Clinical trials: Fungal Infection Lungs
Bronchoalveolar Lavage Fluid, Lung Infection
Diagnosis of Lung Complication After Allo-HSCT by Multiple Parameter System Through BAL
The aim of this study was to evaluate the diagnostic yield for lung complication after allo-HSCT by multiple parameter system through BAL.
- Trial name
- SHSYXY-BAL (NCT04051372)
- Testing
- Bronchoscopic Alveolar Lavage
- Volunteers
- 250 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Invasive Pulmonary Aspergillosis
CYP 2C19 Polymorphism and Voriconazole Trough Concentration in Chinese Adult Patients
To investigate the relationship between cytochrome P450 (CYP) 2C19 genetic polymorphism and the steady-state blood concentration of voriconazole in Chinese patients with invasive pulmonary aspergillosis (IPA), and to assess the…
- Trial name
- NCT02100761
- Testing
- Voriconazole
- Where
- China
- Volunteers
- 200 people
- Sponsor
- dingshifang
Anaemia, Aspergillosis, Allergic Bronchopulmonary
Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Dialysis (ASCEND-D)
The purpose of this multi-center event-driven study in participants with anemia associated with chronic kidney disease (CKD) to evaluate the safety and efficacy of daprodustat.
- Trial name
- NCT02879305
- Testing
- Daprodustat, rhEPO, Iron therapy
- Where
- 462 sites in United States, Argentina and 33 more
- Volunteers
- 2,964 people
- Sponsor
- GlaxoSmithKline
Staphylococcus Aureus
Aurexis® in Cystic Fibrosis Subjects Chronically Colonized With Staphylococcus Aureus in Their Lungs
Patients who are at least 7 years old with stable Cystic Fibrosis who have Staphylococcus aureus in their Lungs will be enrolled into the study and receive one dose of Aurexis® intravenously on Study Day 1, and will be followed…
- Trial name
- NCT00198289
- Testing
- Aurexis® (tefibazumab)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Bristol-Myers Squibb
Pneumonia, Pneumocystis Carinii, HIV Infections
The Safety and Efficacy of Clindamycin and Primaquine in the Treatment of Mild - Moderate Pneumocystis Carinii Pneumonia in Patients With AIDS
To determine the safety and effectiveness of clindamycin and primaquine in the treatment of mild Pneumocystis carinii pneumonia (PCP) in AIDS patients.
- Trial name
- NCT00000717
- Testing
- Primaquine, Clindamycin
- Where
- 7 sites in United States
- Volunteers
- 50 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Pneumonia, Pneumocystis, Coronavirus
Efficacy and Safety of Darunavir and Cobicistat for Treatment of COVID-19
The study aims to evaluate the efficacy and safety of darunavir and cobistastat in the treatment of COVID-19 pneumonia
- Trial name
- DC-COVID-19 (NCT04252274)
- Testing
- Darunavir and Cobicistat
- Where
- 2 sites in China
- Volunteers
- 30 people
- Sponsor
- Shanghai Public Health Clinical Center
Pneumonia, Pneumocystis Carinii, HIV Infections
A Randomized, Double-Blind Study of 566C80 Versus Septra (Sulfamethoxazole/Trimethoprim) for the Treatment of Pneumocystis Carinii Pneumonia in AIDS Patients
To evaluate the effectiveness of atovaquone (566C80) compared to a standard antipneumocystis agent, (SMX/TMP), for the treatment of mild to moderate Pneumocystis carinii pneumonia (PCP) in AIDS patients.
- Trial name
- NCT00000655
- Testing
- Atovaquone, Sulfamethoxazole-Trimethoprim
- Where
- 38 sites in United States, Belgium and 6 more
- Volunteers
- 300 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Pneumonia, Pneumocystis Carinii, HIV Infections
A Study of Two Forms of Pentamidine in HIV-Infected Children Who May Have Pneumocystis Carinii Pneumonia
To evaluate the delivery of a single dose of aerosolized pentamidine to children; to evaluate the tolerance of pentamidine administration by mask; to compare intravenous pentamidine first dose pharmacokinetics (blood levels) in…
- Trial name
- NCT00000974
- Testing
- Pentamidine isethionate
- Where
- 4 sites in United States
- Volunteers
- 16 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Pneumocystis Pneumonia
Effects and Safety of Caspofungin and Corticosteroids in Pneumocystis Pneumonia in Non-HIV Patients
Pneumocystis Pneumonia is increasing in Immunocompromised Non-HIV Infected Patients. The effects and safety of caspofungin and corticosteroids is not certain in this population.
- Trial name
- NCT02603575
- Testing
- caspofungin, corticosteroids, Sulfanilamides
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Beijing Chao Yang Hospital
Opportunistic Fungal Infections
Comprehensive Diagnosis and Treatment Strategy for Opportunistic Fungal Infections in AIDS Patients
Opportunistic fungal infection is the most common opportunistic infection in AIDS patients, with the high mortality and recurrence rate due to the lack of standardized comprehensive diagnosis and treatment strategy.
- Trial name
- NCT05153005
- Testing
- examination methods
- Where
- China
- Volunteers
- 600 people
- Sponsor
- Guangzhou 8th People's Hospital
Aspergillosis
A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of PC945
PC945 is a new medicine being developed for treatment of fungal lung diseases. The main purpose of this study is to investigate the safety, tolerability and pharmacokinetics of single and repeat doses of PC945
- Trial name
- NCT02715570
- Testing
- PC945 - single doses, PC945 - repeat doses
- Where
- United Kingdom
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Pulmocide Ltd
Cystic Fibrosis, Allergic Bronchopulmonary Aspergillosis
An Exploratory Study to Assess Multiple Doses of Omalizumab in Patients With Cystic Fibrosis Complicated by Acute Bronchopulmonary Aspergillosis (ABPA)
This study will evaluate the safety and efficacy of omalizumab for the treatment of Allergic Bronchopulmonary Aspergillosis (ABPA) in patients with Cystic Fibrosis aged 12 years and older.
- Trial name
- NCT00787917
- Testing
- Omalizumab, Itraconazole
- Where
- 10 sites in Belgium, Germany and 3 more
- Volunteers
- 14 people
- Sponsor
- Novartis Pharmaceuticals
Fungal Infection Lungs
Risk of Aspergillus Infection in Patients With Chronic Lung Disease
Large doses of systemic corticosteroids ，severe lung tissue damage and longer COPD diagnosis may increase the risk of IPA in patients with chronic structural lung disease.
- Trial name
- NCT06379568
- Testing
- No intervention
- Where
- China
- Volunteers
- 209 people
- Sponsor
- Lin Chen
IFI
Treatment Method Research of Invasive Pulmonary Fungal Infection
The purpose of this study is to Comparison clinical efficiency with IPFI patients who treated by different protocols(empirical therapy or preemptive therapy) in ICU.
- Trial name
- 4056 (NCT01693887)
- Where
- 4 sites in China
- Volunteers
- 7 people
- Sponsor
- West China Hospital
Pneumonia, Pneumocystis Carinii, HIV Infections
A Treatment IND for 566C80 Therapy of Pneumocystis Carinii Pneumonia
To facilitate provision of atovaquone (566C80) to patients who have mild to moderate Pneumocystis carinii pneumonia (PCP) and are intolerant and/or unresponsive to trimethoprim / sulfamethoxazole (TMP / SMX ); to monitor serious…
- Trial name
- NCT00001991
- Testing
- Atovaquone
- Where
- United States
- Sponsor
- Glaxo Wellcome
Diphtheria, Acellular Pertussis
Impact of Boostrix™ Maternal Vaccination on Morbidity and Mortality of Pertussis Disease in Infants ≤6 Weeks of Age, in Bogota, Colombia.
This study is being conducted to assess impact of maternal immunisation against pertussis in infants ≤12 months of age before and after introduction of pertussis maternal immunisation in Bogota, Colombia from January…
- Conditions
- Diphtheria, Acellular Pertussis, Tetanus, Aspergillosis, Allergic Bronchopulmonary
- Trial name
- NCT02569879
- Testing
- Pertussis maternal immunization
- Where
- Colombia
- Volunteers
- 1 people
- Sponsor
- GlaxoSmithKline
Infections, Streptococcal
Identification and Characterization of Bacteria in the Lungs of Children From 6 Months up to 6 Years Old, With Suspected Infection of the Lungs, in Spain.
The purpose of this study is to identify and characterise bacteria present in the lower airways of children with suspected chronic LRTIs and for whom bronchoalveolar lavage (BAL) is indicated by the clinician.
- Trial name
- NCT02838407
- Testing
- BAL fluid sampling, Nasopharyngeal swab sampling
- Where
- 7 sites in Spain
- Volunteers
- 197 people
- Sponsor
- GlaxoSmithKline
Allergic Bronchopulmonary Aspergillosis (ABPA)
Pathogenesis and Inflammatory Phenotype of Allergic Bronchopulmonary Aspergillosis
This study aims to reveal the immune and inflammatory regulatory molecular mechanisms related to the progression of allergic bronchopulmonary aspergillosis (ABPA), and to build a precision typing based on inflammation and…
- Trial name
- NCT07040332
- Where
- China
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- Qianfoshan Hospital
Pneumocystis
Pneumocystis in Patients Over 75 Year
Pneumocystis pneumonia is an infectious disease caused by Pneumocystis jirovecii that affects the lung parenchyma preferentially. Historically described in an immunocompromised population through HIV.
- Trial name
- C_PAPY (NCT07004127)
- Where
- France
- Volunteers
- 162 people
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
ABPA, Severe Asthma
Benralizumab in the Treatment of Patients With Severe Asthma With ABPA
Phase IV, open-label study will evaluate effects of Benralizumab in the treatment of severe asthma in patients with allergic bronchopulmonary aspergillosis
- Conditions
- ABPA, Severe Asthma, Allergic Bronchopulmonary Aspergillosis
- Trial name
- NCT04108962
- Testing
- Fasenra, 30 Mg/mL Subcutaneous Solution
- Where
- United States
- Sponsor
- Baylor Research Institute